PLX - Wutah dodolan YoY (TTM) Protalix BioTherapeutics

Stable demand for unique therapies for rare pathologies ensures revenue predictability for Protalix BioTherapeutics (PLX). Looking at the annual sales growth rate over a 12-month period on GURU.Markets, the current figure stands at 37.00. Growth is supported by alliances with pharma behemoths via the ProCellEx system, while an asset-light model featuring royalties from biologics effectively scales business margins.

Protalix BioTherapeutics' sustainable approach to developing plant-cell-based drugs determines the scaling potential of its commercial operations. By analyzing the historical year-over-year revenue growth trend over the last 12 months, an investor can see the percentage change in current total income relative to the same period last year, which allows for the differentiation of the business maturity stage and an assessment of the company's expansion sustainability.